ATOS חוב כולל להון Atossa

Atossa Therapeutics (ATOS) is mitigating risks by developing advanced hormonal therapies to combat breast tumors. Despite the lack of profitability, existing reserves are sufficient to complete current clinical trials. This price chart on GURU.Markets confirms the management's financial discipline: there is no debt, and the indicator stands at 0.00, highlighting the transparency of capital management within the women's health sector.

The Debt/Equity ratio measures the proportion of borrowed funds relative to equity, determining the business's degree of financial leverage. Low indebtedness is critical for biotechnology, where patents for anti-cancer drugs create the foundation for future monopoly profits. By analyzing the financial stability ratio chart, an investor assesses the balance between bankruptcy risks and growth rates. Debt optimization allows Atossa Therapeutics (ATOS) to effectively capitalize its developments, confirming the fundamental reliability of the company's capital structure.